EUVIMEDEUVIMED entdecken
Open Access

Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma

Ye Sheng, Qing Wang, HaiFeng Liu, Qi Wang, WenHua Chen, Wei Xing iD

British Journal of Radiology · 28.02.2024 · 97 (1155) · 668-679

DOI: 10.1093/bjr/tqae018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 25.01.2024. Verfasst von Ye Sheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Juqian street NO.185, Ti…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Phenylurea Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Youth Project Fund of Changzhou City Health Commission, Interventional Medicine Scientific Research Special Fund Project of Jiangsu Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To establish and verify a prognostic nomogram model for selecting in unresectable hepatocellular carcinoma (uHCC) treated by transarterial chemoembolization plus lenvatinib (TACE-L) with or without PD-1 inhibitor.

Methods

Data of 241 uHCC patients who underwent TACE-L (n = 128) and TACE-L plus PD-1 inhibitor (TACE-L-P, n = 113) were retrospectively reviewed. The differences in tumour responses, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) between two groups were compared, and a prognostic nomogram model was established based on independent clinical-radiologic factors and confirmed by Cox regression analysis for predicting PFS and OS. The treatment selection for uHCC patients was stratified by the nomogram score.

Results

Compared to TACE-L, TACE-L-P presented prolonged PFS (14.0 vs. 9.0 months, P < .001), longer OS (24.0 vs. 15.0 months, P < .001), and a better overall objective response rate (54.0% vs. 32.8%, P = .001). There was no significant difference between the rate of AEs in the TACE-L-P and the TACE-L (56.64% vs. 46.09%, P = .102) and the rate of grade ≥ 3 AEs (11.50% vs. 9.38%, P = .588), respectively. The nomogram model presented good discrimination, with a C-index of 0.790 for predicting PFS and 0.749 for predicting OS. Patients who underwent TACE-L and obtained a nomogram score >9 demonstrated improved 2-year PFS when transferred to TACE-L-P, and those with a nomogram ≤25 had better 2-year OS when transferred to TACE-L-P.

Conclusions

TACE-L-P showed significant improvements in efficiency and safety for uHCC patients compared with TACE-L. The nomogram was useful for stratifying treatment decisions and selecting a suitable population for uHCC patients. Advances in knowledge Prognostic nomogram model is of great value in predicting individualized survival benefits for uHCC patients after TACE-L or/and TACE-L-P. And the nomogram was helpful for selection between TACE-L-P and TACE-L among uHCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticPhenylurea CompoundsQuinolinesHumansPrognosisNomogramsImmune Checkpoint InhibitorsRetrospective Studies

Stichwörter der Autor:innen

PD-1 inhibitorhepatocellular carcinomalenvatinibnomogram modeltransarterial chemoembolization (TACE)

Substanzen

Immune Checkpoint InhibitorslenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Interventional Radiology, Third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
  • Department of Radiology, Third Affiliated Hospital of Soochow University, Changzhou & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.

ORCID-Profile: Wei Xing

Förderung

  • Youth Project Fund of Changzhou City Health Commission
  • Interventional Medicine Scientific Research Special Fund Project of Jiangsu Medical Association

Zitieren

APA

Sheng, Y., Wang, Q., Liu, H., Wang, Q., Chen, W., & Xing, W. (2024). Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma. British Journal of Radiology, 97(1155), 668-679. https://doi.org/10.1093/bjr/tqae018

Vancouver

Sheng Y, Wang Q, Liu H, Wang Q, Chen W, Xing W. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma. British Journal of Radiology. 2024;97(1155):668-679. doi:10.1093/bjr/tqae018

BibTeX
@article{Sheng2024,
  author = {Sheng, Ye and Wang, Qing and Liu, HaiFeng and Wang, Qi and Chen, WenHua and Xing, Wei},
  title = {Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma},
  journal = {British Journal of Radiology},
  year = {2024},
  volume = {97},
  number = {1155},
  pages = {668--679},
  doi = {10.1093/bjr/tqae018}
}
Kostenlos starten →